Skip to main content
. 2010 Nov 4;5(11):e13834. doi: 10.1371/journal.pone.0013834

Figure 5. The combination treatment of retinoic acids and/or SL142 or SL325 synergically increased the transcriptional activity of RARE in H441 lung cancer cells.

Figure 5

A. Transient transfection reporter assays in H441 cells with pGL4. or pGL4.RARE 7x (2 µg), plus pCMV. β-galactosidase (2 µg) after retinoic acids (2.5 µM) and/or SL142 or SL325 (0.5 µM) retinoic acids treatment. Results are presented as fold induction of relative light units normalized to β-galactosidase activity relative to that observed for control constructs. #, significant difference from the promoter activity generated by pGL4.RARE 7x after ATRA and SAHA treatment (p<0.05). *, significant difference from the promoter activity generated by pGL4.RARE 7x after 9-cis RA and SAHA treated cells (p<0.05). B. Immunoblot analysis of RARα, RARβ, RXRα and RXRβ expressions after retinoic acids and/or SL142 or SL325 treatment in H441 lung cancer cells. Human lung cancer cells were harvested 24 hours after treatment with ATRA or 9-cis RA (2.5 µM) or/and SAHA, SL142 or SL325 (0.5 µM). β-actin is shown as control.